SALT LAKE CITY, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of
data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments,
announces that it has acquired DNA and ancestry assets, including significant genetic data related to women’s diseases and
degenerative disc disease from Taueret Laboratories, LLC.
The acquired assets include: (i) approximately 1,000 degenerative disc disease-related DNA samples, related family records,
relevant clinical records (including approximately 600 affected probands) and 800 ancestry matched control samples, (ii) whole
exome sequencing data on approximately 300 degenerative disc disease samples, over 800 local controls, and published reference
populations, together with initial analysis of the markers, and (iii) exclusive use of a DNA biobank that has collected over
300,000 samples for multiple diseases that the Company may target.
“Although our focus remains on endometriosis, the acquisition of these key DNA and ancestry assets significantly strengthens our
development platforms to commercialize gene-based diagnostics and biotechnology treatments for other debilitating diseases, such as
additional difficult-to-diagnose women’s health diseases and degenerative disc disease,” said Bradley Robinson, CEO of Predictive
Technology Group. “These assets are complementary to our recent acquisition of Inception Dx, which included ancestry database
records for over 31.9 million individuals for use in genetics research. With Inception Dx, we are now positioned to further
develop the assets acquired from Taueret Laboratories.”
About Endometriosis:
Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar
to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and
inflammation caused by these lesions may severely impact a woman's quality of life. Some affected women experience severe pain,
others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires
surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with
endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted
destruction of the abnormal tissue during surgery.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These
subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The
subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of
illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is
available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new
product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional
intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may
identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
